Clinical, therapeutic interventions for the treatment of hypertension, heart failure, and post–myocardial infarction remodeling have successfully used MR antagonists.1,2 However, the benefit of this class of drugs could extend to the treatment of other cardiovascular diseases, like ischemic stroke. The gene discussed is NR3C2; the disease is ischemic stroke.